Hematocon 2021

This early clinical investigation focused on the administration and effectiveness of low-dose Nivolumab specifically for patients with relapsed and refractory Hodgkin Lymphoma. As a single-center experience, it detailed the response rates, patient tolerance, and clinical efficacy observed when utilizing a reduced-dose strategy in a specialized haematology setting.

The presentation highlighted the potential of implementing reduced-dose protocols to achieve therapeutic responses in patients who have not responded to initial lines of treatment. This foundational work provided important insights into the clinical utility of low-dose immunotherapy and the role of single-center experiences in shaping evidence-based practices for treating aggressive haematological conditions.

Upcoming Events